Compare AMG & CAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMG | CAI |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 9.7B |
| IPO Year | 1997 | 2025 |
| Metric | AMG | CAI |
|---|---|---|
| Price | $388.97 | $21.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $466.71 | $34.23 |
| AVG Volume (30 Days) | 304.6K | ★ 3.8M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.01% | N/A |
| EPS Growth | 50.30 | ★ 69.79 |
| EPS | ★ 17.38 | 0.05 |
| Revenue | ★ $2,074,400,000.00 | $812,033,000.00 |
| Revenue This Year | $17.42 | $28.81 |
| Revenue Next Year | $9.39 | $19.11 |
| P/E Ratio | ★ $22.70 | $460.40 |
| Revenue Growth | 1.64 | ★ 96.97 |
| 52 Week Low | $246.11 | $14.19 |
| 52 Week High | $408.07 | $36.50 |
| Indicator | AMG | CAI |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 27.92 |
| Support Level | $340.19 | $16.52 |
| Resistance Level | $396.01 | $23.66 |
| Average True Range (ATR) | 15.28 | 2.00 |
| MACD | 1.14 | -1.21 |
| Stochastic Oscillator | 64.06 | 0.03 |
Affiliated Managers Group offers investment strategies to investors through its network of affiliates. The firm typically buys a majority interest in small to mid-size boutique asset managers, receiving a fixed percentage of revenue from these firms in return. Affiliates operate independently, with AMG providing strategic, operational, and technology support, as well as global distribution. At the end of June 2026, AMG's affiliate network—which includes firms like Abacus Capital and Pantheon dedicated to private markets (which accounted for 16% of AUM), AQR Capital and Capula Investment Management in liquid alternatives (31%), and Harding Loevner, Tweedy Browne, Parnassus, and Yacktman in equities, multi-asset, and bond strategies (53%)—had $942.4 billion in managed assets.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.